Onset of activity and time to response on individual CAPS-SX 17 items in patients treated for post-traumatic stress disorder with venlafaxine ER: A pooled analysis

International Journal of Neuropsychopharmacology

Volumn 12, Issue 1, 2009, Pages 23-31

  Stein, Dan J ^a,f   Pedersen, Ron ^b   Rothbaum, Barbara O ^c   Baldwin, David S ^d   Ahmed, Saeeduddin ^b   Musgnung, Jeff ^b   Davidson, Jonathan ^e  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b PFIZER INC   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

PTSD; Response; Venlafaxine

Indexed keywords

VENLAFAXINE; CYCLOHEXANOL DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ANALYTIC METHOD; ANGER; ARTICLE; CLINICAL TRIAL; CLINICIAN ADMINISTERED POSTTRAUMATIC STRESS DISORDER SCALE; CONTROLLED CLINICAL TRIAL; DISTRESS SYNDROME; DRUG DOSE INCREASE; DRUG EFFECT; DRUG FORMULATION; DRUG RESPONSE; EXTENDED RELEASE FORMULATION; FEMALE; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; POOLED ANALYSIS; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RATING SCALE; SYMPTOM; ADOLESCENT; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DOUBLE BLIND PROCEDURE; ETHNIC GROUP; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; ETHNIC GROUPS; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 61949346363     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145708008961     Document Type: Article

References (27)

1. Allgulander C, Hackett D, Salinas E (2001). Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. British Journal of Psychiatry 179, 15-22.
2. APA (2000). Diagnostic and Statistical Manual of Mental Disorders, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association.
3. Bond AJ (2005). Antidepressant treatments and human aggression. European Journal of Pharmacology 526, 218-225.
4. Charney DS (2004). Psychobiological mechanisms of resilience and vulnerability: implications for successful adaptation to extreme stress. qAmerican Journal of Psychiatry 161, 195-216.
5. David D, De Faria L, Mellman TA (2006). Adjunctive risperidone treatment and sleep symptoms in combat veterans with chronic PTSD. Depression & Anxiety 23, 489-491.
6. Davidson J, Baldwin D, Stein DJ, Kuper E, Benattia I, Ahmed S, Pedersen R, Musgnung J (2006a). Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized, controlled trial. Archives of General Psychiatry 63, 1158-1165.
7. Davidson J, Landerman LR, Clary CM (2004). Improvement of anger at one week predicts the effects of sertraline and placebo in PTSD. Journal of Psychiatric Research 38, 497-502.
8. Davidson J, Rothbaum BO, Tucker P, Asnis G, Benattia I, Musgnung JJ (2006b). Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. Journal of Clinical Psychopharmacology 26, 259-267.
9. Davidson JR, DuPont RL, Hedges D, Haskins JT (1999). Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. qJournal of Clinical Psychiatry 60, 528-535.
10. Davidson JR, Landerman LR, Farfel GM, Clary CM (2002). Characterizing the effects of sertraline in post-traumatic stress disorder. Psychological Medicine 32, 661-670.
11. Davis LL, Suris A, Lambert MT, Heimberg C, Petty F (1997). Post-traumatic stress disorder and serotonin: new directions for research and treatment. Journal of Psychiatry and Neuroscience 22, 318-326.
12. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E (2000). Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. Journal of the American Medical Association 283, 3082-3088.
13. Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB (1995). Posttraumatic stress disorder in the National Comorbidity Survey. Archives of General Psychiatry 52, 1048-1060.
14. Kozaric-Kovacic D, Pivac N, Muck-Seler D, Rothbaum BO (2005). Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial. Journal of Clinical Psychiatry 66, 922-927.
15. Liebowitz MR, Gelenberg AJ, Munjack D (2005). Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Archives of General Psychiatry 62, 190-198.
16. Londborg PD, Hegel MT, Goldstein S, Goldstein D, Himmelhoch JM, Maddock R, Patterson WM, Rausch J, Farfel GM (2001). Sertraline treatment of posttraumatic stress disorder: results of 24 weeks of open-label continuation treatment. Journal of Clinical Psychiatry 62, 325-331.
17. Maher MJ, Rego SA, Asnis GM (2006). Sleep disturbances in patients with post-traumatic stress disorder: epidemiology, impact and approaches to management. CNS Drugs 20, 567-590.
18. Meltzer-Brody S, Connor KM, Churchill E, Davidson JR (2000). Symptom-specific effects of fluoxetine in post-traumatic stress disorder. qInternational Clinical Psychopharmacology 15, 227-231.
19. Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G, Tzanis E, Salinas E, Whitaker T, Gao B (2007). A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depression & Anxiety 24, 1-14.
20. Raskind MA, Peskind ER, Hoff DJ, Hart KL, Holmes HA, Warren D, Shofer J, O'Connell J, Taylor F, Gross C, et al. (2007). A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biological Psychiatry 61, 928-934.
21. Rickels K, Pollack MH, Sheehan DV, Haskins JT (2000). Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. American Journal of Psychiatry 157, 968-974.
22. Shay J (1992). Fluoxetine reduces explosiveness and elevates mood of Vietnam combat vets with PTSD. Journal of Traumatic Stress 5, 97-101.
23. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I (2002). Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. British Journal of Psychiatry 180, 396-404.
24. Stein DJ, Ipser JC, Seedat S (2006). Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database of Systematic Reviews. Issue 1. Art No.: CD002795.
25. Stein MB, Kline NA, Matloff JL (2002). Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. American Journal of Psychiatry 159, 1777-1779.
26. Thase ME, Entsuah AR, Rudolph RL (2001). Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. British Journal of Psychiatry 178, 234-241.
27. Ursano RJ, Bell C, Eth S, Friedman M, Norwood A, Pfefferbaum B, Pynoos JD, Zatzick DF, Benedek DM, McIntyre JS, et al. (2004). Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. American Journal of Psychiatry 161 (11 Suppl.), 2-57.